Of humans and canines: Immunohistochemical analysis of PCNA, Bcl-2, p53, cytokeratin and ER in mammary tumours

Research in Veterinary Science

Volumn 81, Issue 2, 2006, Pages 218-224

  Kumaraguruparan, R ^a   Prathiba, D ^b   Nagini, S ^a  

^a ANNAMALAI UNIVERSITY   (India)

^b SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

Bcl 2; Breast cancer; Cytokeratin; ER; p53; PCNA

Indexed keywords

CYCLINE; CYTOKERATIN; ESTROGEN RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER PATIENT; CANCER TISSUE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOG; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR MECHANICS; NONHUMAN; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TUMOR MODEL;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MAMMARY NEOPLASMS, ANIMAL; MIDDLE AGED; NEOPLASM STAGING; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

CANIDAE;

EID: 33746916455     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2005.08.002     Document Type: Article

References (48)

1. Alfred D., Mohsin S., and Fuqua S. Histological and biological evolution of human premalignant breast disease. Endocrine-Related Cancer 8 (2001) 47-61
2. Anderson E., Clarke R., and Howell A. Estrogen responsiveness and control of normal human breast proliferation. Journal of Mammary Gland Biology and Neoplasia 3 (1998) 23-35
3. Baccouche S., Daoud J., Frikha M., Mokdad-Gargouri R., Gargouri A., and Jlidi R. Immunohistochemical status of P53, MDM2, bcl-2, bax and ER in invasive ductal breast cacinoma in Tunisian patients. Annals of the New York Academy of Sciences 1010 (2003) 752-763
4. Balasenthil S., Rao K.S., and Nagini S. Altered cytokeratin expression during chemoprevention of experimental hamster buccal pouch carcinogenesis by garlic. Journal of Oral Pathology and Medicine 31 (2002) 142-146
5. Battifora H., Sun T.-T., Bahu R.M., and Rao S. The use of antikeratin antiserum as a diagnostic tool: thymoma versus lymphoma. Human Pathology 11 (1980) 635-641
6. Chunder N., Mandal S., Basu D., Roy A., Roychoudhury S., and Panda C.K. Deletion mapping of chromosome 1 in early onset and late onset breast tumours - a comparative study in eastern India. Pathology Research and Practice 199 (2003) 313-321
7. Coyle Y.M. The effect of environment on breast cancer risk. Breast Cancer Research Treatment 84 (2004) 273-288
8. Eissa S., Labib R., Khalifa A., Swelam N., Khalil F., and El-Shenawy A.M. Regulators in human breast cancer. Clinical Biochemistry 32 (1999) 321-326
9. Franzen B., Linder S., Alaiya A.A., Eriksson E., Uruy K., Hirano T., Okuzawa K., and Auer G. Analysis of polypeptide expression in benign and malignant human breast lesions: down-regulation of cytokeratins. British Journal of Cancer (1996) 1632-1638
10. Franzen B., Linder S., Alaiya A.A., Eriksson E., Fujioka K., Bergman A.C., Jornvall H., and Auer G. Analysis of polypeptide expression in benign and malignant human breast lesions. Electrophoresis 18 (1997) 582-587
11. Funakoshi Y., Nakayama H., Uetsuka K., Nishimura R., Sasaki N., and Doi K. Cellular proliferative and telomerase activity in canine mammary gland tumours. Veterinary Pathology 37 (2000) 177-183
12. Gajalakshmi C.K., Shantha V., Swaminathan R., Sankaranarayanan R., and Black R.J. A population-based survival study on female breast cancer in Madras, India. British Journal of Cancer 75 (1997) 771-775
13. Grossi F., Loprevite M., Chiaramondia M., Ceppa P., Pera C., Ratto G.B., Serrano J., Ferrara G.B., Costa R., Boni L., and Ardizzoni A. Prognostic significance of K- ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. European Journal of Cancer 39 (2003) 1242-1250
14. Gupta A., Malati T., and Gupta P.D. Altered expression of keratin in epithelioid tumours. Current Science 62 (1992) 288-293
15. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
16. Hampe J.F., and Misdorp W. Tumours and dysplasias of the mammary gland. Bulletin World Health Organization 50 (1974) 111-133
17. Heyden A., Huitfeidt H.S., Koppang H.S., Thrane P.S., Bryne M., and Brandtzaeg P. Cytokeratins as epithelial differentiation markers in premalignant and malignant lesions. Journal of Oral Pathology and Medicine 21 (2000) 7-11
18. Ivanyi D., Groeneveld E., van Doornward G., Mooi W.J., and Hageman P.C. Keratin subtypes in carcinomas of the uterine cervix: implications for histogenesis and differential diagnosis. Cancer Research 50 (1990) 5143-5152
19. Kirkin V., Joos S., and Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochimica et Biophysica Acta 1644 (2004) 229-249
20. Kumaraguruparan R., Balachandran C., Murali Manohar B., and Nagini S. Altered oxidant-antioxidant profile in canine mammary tumours. Veterinary Research Communications 29 (2005) 287-296
21. Kumaraguruparan R., Kabalimoorthy J., and Nagini S. Correlation of lipid peroxidation and antioxidants with clinical stage and menopausal status in patients with adenocarcinoma of the breast. Clinical Biochemistry 38 (2005) 154-158
22. Kumaraguruparan, R., Subapriya, R., Balachandran, C., Murali Manohar, B., Thangadurai, A., Nagini, S., 2005. Xenobiotic-metabolizing enzymes in canine mammary tumours. The Veterinary Journal, in press.
23. Kumaraguruparan R., Chandra Mohan K.V.P., and Nagini S. Xenobiotic-metabolizing enzymes in patients with adenocarcinoma of the breast: correlation with clinical stage and menopausal status. The Breast 15 (2006) 58-63
24. Lee C.H., Kim W.H., Lim J.H., Kang M.S., Kim D.Y., and Kweon O.K. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumours. Journal of Veterinary Science 5 (2004) 63-69
25. Linjawi A., Kontogiannea M., Halwani F., Edwardes M., and Meterissian S. Prognostic significance of p53, Bcl-2 and Bax expression in early breast cancer. Journal of the American College of Surgeons 198 (2004) 83-90
26. Maga G., and Hübscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. Journal of Cell Science 116 (2003) 3051-3060
27. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., and Moll U.M. P53 has a direct apoptogenic role at the mitochondria. Molecular Cell 11 (2003) 577-590
28. Mullas M.D., Millan Y., and Dios R. A prospective analysis of immunohistochemically determined estrogen receptor {alpha} and progesterone receptor expression and host and tumour factors as predictors of disease-free period in mammary tumours of the dog. Veterinary Pathology 42 (2005) 200-212
29. Murphy L.C., and Watson P. Steroid receptors in human breast carcinogenesis and breast cancer progression. Biomedicine and Pharmacotherapy 56 (2002) 65-77
30. Nerurkar V.R., Chitale A.R., Jalnapurkar B.V., Naik S.N., and Lalitha V.S. Comparative pathology of canine mammary tumours. Journal of Comparative Pathology 101 (2003) 389-397
31. Nieto A., Perez-Alenza M.D., Del Castillo N., Tabanera E., Castano M., and Pena L. BRCA1 expression in canine mammary dysplasis and tumours: relationship with prognostic variables. Journal of Comparative Pathology 128 (2003) 260-268
32. O'Hanlon D.M., Kiely M., MacConmara M., Al-Azzawi R., Connolly Y., Jeffers M., and Keane F.B.V. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma. European Journal of Surgical Oncology 28 (2002) 103-107
33. Ochisi K., Morimatsu M., Tomizawa N., and Syuto B. Cloning and sequencing full length of canine Brca2 and Rad51 cDNA. Journal of Veterinary Medical Science 63 (2001) 1103-1108
34. Ogden G.R. Cytokeratins as tumours makers. Oral Disease 6 (2000) 57-59
35. Okobia M.N., and Bunker C.H. Molecular epidemiology of breast cancer: a review. African Journal of Reproductive Health 7 (2003) 17-28
36. Osborn M., and Weber K. Tumour diagnosis by intermediate filament typing: a novel tool for surgical pathology. Laboratory Investigation 48 (1983) 372-394
37. Owen L.N. A comparative study of canine and human breast cancer. Investigative Cell Pathology 2 (1979) 257-275
38. Owen L.N. TNM classification of tumours in domestic animals. World Health Organization Bulletin (1980) 20-80
39. Paunesku T., Mittal S., Protic M., Oryhon J., Korolev S.V., Joachimiak A., and Woloschak G.E. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. International Journal of Radiation Biology 77 (2001) 1007-1021
40. Pearce S.T., and Jordan V.C. The biological role of estrogen receptors α and β in cancer. Critical Reviews in Oncology/Hematology 50 (2004) 3-22
41. Rungsipipat A., Tateyama S., Yamaguchi R., Uchida K., Miyoshi N., and Hayashi T. Immunohistochemical analysis of c- yes and c- erbB-2 oncogene products and p53 tumour suppressor protein in canine mammary tumours. Journal of Veterinary Medical Science 61 (1999) 27-32
42. Shaw J.A., Udokang K., Mosquera J.M., Chauhan H., Jones J.L., and Walker R.A. Oestrogen receptors alpha and beta in normal human breast and breast carcinomas. Pathology 198 (2002) 450-457
43. Silvestrini R., Benini E., Daidone M.G., Veneroni S., Boracchi P., Cappelletti V., Di Fronzo G., and Veronesi U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. Journal of the National Cancer Institute 85 (1993) 965-970
44. Sonnenschein E.G., Glickman L.T., Goldschmidit M.H., and Mckee L.J. Body conformation, diet and risk of breast cancer in pet dogs: a case control study. American Journal of Epidemiology 133 (1991) 694-703
45. Sorenmo K. Canine mammary gland tumours. Veterinary Clinics Small Animal Practice 33 (2003) 573-596
46. Thor A.D., Moore II D.H., Edgerton S.M., Kawasaki E.S., Reihsaus E., Lynch H.T., Marcus J.N., Schwartz L., Chen L.C., and Mayall B.H. Accumulation of p53 tumour suppressor gene protein: an independent marker of prognosis in breast cancers. Journal of the National Cancer Institute 84 (1992) 845-855
47. WHO, 1997. The World Health Report, Geneva: WHO.
48. World Health Organisation, 1981. Histological typing of breast tumours. International histological classification tumours, second ed. World Health Organisation, Geneva.